Telix share price hits record high on strong quarter and guidance upgrade

This market darling has continued to deliver stunning top line growth.

| More on:
Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is rising again on Thursday morning.

In early trade, the radiopharmaceuticals company's shares have hit a record high of $20.76.

Why is the Telix share price at a record high?

Investors have been bidding the company's shares higher this morning after it released an update on its performance during the second quarter.

According to the release, for the three months ended 30 June, Telix achieved total revenue of approximately US$124 million (A$189 million) This represents an increase of 55% on the prior corresponding quarter and an 8% increase on the previous quarter.

Management advised that this revenue was primarily generated from sales of Telix's prostate cancer imaging product Illuccix in the United States.

Revenue generated from sales of Illuccix in the United States was approximately US$121 million during the three months.

Guidance upgraded

In light of this strong performance, the company has upgraded its revenue guidance for FY 2024.

It now expects revenue to be in the range of US$490 million to US$510 million (A$745 million to A$776 million at current exchange rates). This represents an increase of approximately 48% to 54% on FY 2023's revenue.

Telix was previously guiding to revenue of US$445 million to US$465 million for FY 2024, which means it has lifted its guidance by a sizeable 9.9% at the mid-point. This helps explain why the Telix share price is outperforming today.

This revenue guidance is based on approved products in jurisdictions with a marketing authorisation. Telix has also reaffirmed its guidance for research and development expenditure, which remains at an expected 40% to 50% increase compared with 2023. This will be funded by earnings.

The company's managing director and CEO, Dr Christian Behrenbruch, was rightfully pleased with the quarter. He said:

We have continued to deliver excellent quarterly growth in both revenue and dose volume sales of Illuccix. We have leveraged our unrivalled scheduling flexibility and clinical differentiation, to increase our market share and minimise the impact of new entrants.

Further information, such as profitability, was not released with this update. However, investors won't have to wait long to see if Telix's strong profit growth continued during the quarter.

The company revealed that it plans to release its half year results for the six months ended 30 June on 22 August.

Following today's gain, the Telix share price is now 70% over the past 12 months.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Bell Potter names the best ASX healthcare shares to buy in 2026

Healthy returns could be on offer with these shares according to the broker.

Read more »

man cupping ear as if to listen closely, rumour, cochlear
Healthcare Shares

Why is everyone talking about Telix shares this week?

Let's see why this biotech stock has been on the move this week.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »

ecommerce asx shares represented by santa doing online shopping on laptop
Healthcare Shares

Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »